Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
05/2005
05/26/2005WO2005030127A3 Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
05/26/2005WO2005020901A3 Delivery of a therapeutic agent in a formulation for reduced toxicity
05/26/2005WO2005018537A3 Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting ap-1 transcription factors
05/26/2005WO2005016246A3 Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases
05/26/2005WO2005009374A8 Ceramide dependent-stabilization of bace1
05/26/2005WO2005009363A3 Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies
05/26/2005WO2005009361A3 Method of treating hit patients with argatroban
05/26/2005WO2005009217A3 Diagnosis of pre-cancerous conditions using pcdgf agents
05/26/2005WO2005007082A3 Treatment of chronic bacterial infection
05/26/2005WO2005000245A3 Compositions and methods for increasing telomerase activity
05/26/2005WO2005000209A3 An improved method and apparatus for dosing single and multi-agent therapy
05/26/2005WO2005000207A3 Pcdgf receptor antibodies and methods of use thereof
05/26/2005WO2004112719A8 Chemical compounds
05/26/2005WO2004112695B1 Methods and compositions for delivery of catecholic butanes for treatment of obesity
05/26/2005WO2004103294A3 Methods and compositions for the prevention and treatment of sepsis
05/26/2005WO2004098524A3 Lipid platinum complexes and methods of use thereof
05/26/2005WO2004091538B1 Homogeneous, thermoreversible alginate films and soft capsules made therefrom
05/26/2005WO2004089299A3 Pulsatile transdermally administered antigens and adjuvants
05/26/2005WO2004082619A3 Forms of 5-azacytidine
05/26/2005WO2004080412A3 Paclitaxel hybrid derivatives
05/26/2005WO2004073617A3 Tertiary amine functional complex polyester polymers
05/26/2005WO2004073604A3 Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity
05/26/2005WO2004056312A3 Immunoglobulin variants and uses thereof
05/26/2005US20050114912 Model for neurodegenerative disorders
05/26/2005US20050113585 novel intermediates useful in the synthesis of 14 beta -hydroxy-1,14-carbonate-deacetylbaccatin III derivatives; 7,10-bistrichloroacetyl-10-deacetylbaccatin III; 13-dehydro-14 beta -hydroxy-7-triethylsilylbaccatin III; 13-dehydro-14 beta -hydroxy-7,10-bistrichloroacetyl-baccatin III 1,14-carbonate
05/26/2005US20050113574 Contains 1-(2-Aminoethyl)piperidine and 2-adamantanone; mycobacterial infections
05/26/2005US20050113565 Pegylated factor VII glycoforms
05/26/2005US20050113449 Hydrophobic carriers may increase the rate in which omega-3 fatty acids provide an effect, e.g., by administration by parenteral routes or by protection from degradation or increase of absorption in the gastrointestinal tract
05/26/2005US20050113434 Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury
05/26/2005US20050113409 Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
05/26/2005US20050113401 Use of e.g. N-[(1R,S)-1-Cyclopropylethyl]-Normorphine for treating opiate, cocaine, or alcohol addiction
05/26/2005US20050113356 Inhibitors of cathepsin S
05/26/2005US20050113345 Amidoalkyl phosphates, e.g., 3-(lauramido-3-hexylpropoxy)-2-lauramidopropyl 2-([3-p-hydroxyphenyl)-2-carboxypropionylamino]ethyl phosphate; used for treating inflammatory conditions such as inflammatory bowel disease and for identifying agents that inhibit activation of Toll-like receptor 2
05/26/2005US20050113319 11-Deoxy-6,9-ether erythromycin compounds
05/26/2005US20050113311 Comprises N-alpha-acetyl-L-histidine; kits; droppers
05/26/2005US20050113302 Cardioprotective protein (A3P) or A3 receptor-mediated cardioprotective protein isoform (A3PI) exhibiting an altered expression in cardiac tissue in response to exposure to an A3 agonist; useful for clinical screening, diagnosis, prognosis, therapy, and prophylaxis
05/26/2005US20050112200 improved absorption, bioavailabilty and/or half-life ; treatment or prevention of atherosclerosis or for the treatment of heavy metal accumulation
05/26/2005US20050112193 Immediate-release formulations of acid-labile pharmaceutical compositions
05/26/2005US20050112151 Skin adherent hydrogels
05/26/2005US20050112102 Viral proteins which stimulating immunology response
05/26/2005US20050112068 Systems and methods for reducing unintended use of active ingredients in dermal delivery devices
05/26/2005US20050110644 Enuresis device with magnetic fastener
05/26/2005CA2547474A1 Genes differentially expressed by acutely isolated resident progenitor cells of the human white matter
05/26/2005CA2545876A1 Crystalline topotecan hydrochloride product and process for making the same
05/26/2005CA2545858A1 Variable appearance tissue markings
05/26/2005CA2545731A1 Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders
05/26/2005CA2545709A1 Methods and compositions for the treatment of b cell lymphomas and other cancers
05/26/2005CA2545435A1 Hydroxy piperidine derivatives to treat gaucher disease
05/26/2005CA2545433A1 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
05/26/2005CA2545260A1 Compositions and methods for modulating c-rel-dependent cytokine production
05/26/2005CA2545259A1 Heteroaryl-hydrazone compounds
05/26/2005CA2545258A1 Pyridine compounds
05/26/2005CA2545187A1 Vegf receptor antagonists
05/26/2005CA2545183A1 Custom vectors for treating and preventing pancreatic cancer
05/26/2005CA2545164A1 Recombinant vectors expressing mucin and carcinoembryoinic antigen
05/26/2005CA2545152A1 Compositions and methods of treating neurological diseases
05/26/2005CA2544981A1 4-phenyl piperidine sulfonyl glycine transporter inhibitors
05/26/2005CA2544816A1 Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
05/26/2005CA2544599A1 Methods of treating eczema
05/26/2005CA2544598A1 Antibodies to cd44 glycoforms and uses thereof
05/26/2005CA2544591A1 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
05/26/2005CA2544589A1 Methods of using and compositions comprising pde4 modulators for the treatment and management of asbestos-related diseases and disorders
05/26/2005CA2544487A1 Multilayer pharmaceutical form with a matrix which influences the delivery of a modulatory substance
05/26/2005CA2544304A1 Electrically activated alteration of body tissue stiffness for breathing disorders
05/26/2005CA2544301A1 Altering the stiffness, size, and/or shape of tissues for breathing disorders and other conditions
05/26/2005CA2544252A1 Stem cell culture medium and method of using said medium and the cells
05/26/2005CA2542547A1 Dietary and other compositions, compounds, and methods for reducing body fat, controlling appetite, and modulating fatty acid metabolism
05/26/2005CA2540725A1 Stimulation of hair growth by ginkgo biloba flavonoids
05/26/2005CA2534342A1 Amino acid prodrugs
05/26/2005CA2530605A1 Pro104 antibody compositions and methods of use
05/25/2005EP1533318A1 Prodrugs of thrombin inhibitors
05/25/2005EP1532254A2 Helper virus-free herpesvirus amplicon particles and uses thereof
05/25/2005EP1532122A1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
05/25/2005EP1531861A2 Mycoplasma gallisepticum formulation
05/25/2005EP1322286B1 Polymeric delivery formulations of leuprolide with improved efficacy
05/25/2005EP1165058B1 Azalide antibiotics for the topical treatment or prevention of ocular infections
05/25/2005EP0966304B1 Site-specific drug delivery
05/25/2005EP0813416B1 Reduction of infarct volume using citicoline
05/25/2005CN1620438A 5, 6-diaryl-pyrazine-2-amide derivatives as CBI antagonists
05/25/2005CN1620430A 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of PPAR-alpha
05/25/2005CN1620310A Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
05/25/2005CN1620291A 3-(imidazolyl)-2-alkoxypropanoic acids as TAFIA inhibitors
05/25/2005CN1203065C Non-yellowing para-tertiaryl-alkyl phenyl substituted triazine and pyrimidine ultraviolet light absorbers
05/25/2005CN1203061C Substituted isoquinolines, its preparing process, medical composition and its use for preparing medicine
05/25/2005CN1202865C Synergistic combination
05/25/2005CN1202843C Narcotic medical composition, preparing process and use thereof
05/25/2005CN1202831C Macrolide formulations for inhalation and use thereof
05/25/2005CN1202828C Use of diphosphonic acid in preparing medicine for treatment of vasculogenesis
05/25/2005CN1202824C Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for preparing medicine for treating hepatitis virus infection
05/25/2005CN1202807C Sunscreen compositions
05/25/2005CN1202806C Antiperspirant composition
05/25/2005CN1202805C Agent for dyeing keratin containing fibers
05/24/2005US6897321 Process for preparing azacycloalkanoylaminothiazoles (LD 137e)
05/24/2005US6897207 Kinase inhibitors; angiogenesis inhibitors, anticancer agents, antiinflammatory agents and chronic obstructive pulmonary disease inhibitors
05/24/2005US6896879 Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
05/24/2005CA2354237C A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (adhd)
05/24/2005CA2037607C Humanised antibodies
05/19/2005WO2005044288A1 Composition for topic use containing an extract of stryphnodendron, its preparation as well as its application
05/19/2005WO2005044201A2 Ph sensitive prodrugs of 2,6-diisopropylphenol
05/19/2005WO2005044200A2 Methods and compositions for treating mcp-1 related pathologies
1 ... 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 ... 295